{
    "symbol": "SLRX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 21:32:13",
    "content": "  Today, we will be making certain forward-looking statements about operating metrics, future expectations, plans, events and circumstances, including statements about our strategy, future operations, the development and effectiveness of our investigational drug candidates, seclidemstat and SP-3164 as well as our targeted protein degradation program and expectations regarding our capital allocation and cash resources as well as asking shareholders to vote before or during the 2022 and our stockholders' meeting taking place on June 15, 2022."
}